Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab (CCTGuide Pilot)
A Pilot Study of Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Sponsor: Abramson Cancer Center at Penn Medicine
Listed as NCT04023110, this PHASE1 trial focuses on Breast Cancer and Cardiomyopathies and remains completed. Sponsored by Abramson Cancer Center at Penn Medicine, it has been updated 15 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
-
Feb 2025 — Nov 2025 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 10 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
Nov 2022 — May 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2019 — Nov 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Abramson Cancer Center at Penn Medicine
- American Heart Association
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .